Refine
Document Type
- Article (27)
- Part of Periodical (7)
- Review (7)
- Monograph/Edited Volume (1)
- Postprint (1)
Keywords
Institute
Background: Antiphospholipid antibodies (aPL) can be detected in asymptomatic carriers and infectious patients. The aim was to investigate whether a novel line immunoassay (LIA) differentiates between antiphospholipid syndrome (APS) and asymptomatic aPL+ carriers or patients with infectious diseases (infectious diseases controls (IDC)). Methods: Sixty-one patients with APS (56 primary, 22/56 with obstetric events only, and 5 secondary), 146 controls including 24 aPL+ asymptomatic carriers and 73 IDC were tested on a novel hydrophobic solid phase coated with cardiolipin (CL), phosphatic acid, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, beta2-glycoprotein I (beta 2GPI), prothrombin, and annexin V. Samples were also tested by anti-CL and anti-beta 2GPI ELISAs and for lupus anticoagulant activity. Human monoclonal antibodies (humoAbs) against human beta 2GPI or PL alone were tested on the same LIA substrates in the absence or presence of human serum, purified human beta 2GPI or after CL-micelle absorption. Results: Comparison of LIA with the aPL-classification assays revealed good agreement for IgG/IgM a beta 2GPI and aCL. Anti-CL and anti-beta 2GPI IgG/IgM reactivity assessed by LIA was significantly higher in patients with APS versus healthy controls and IDCs, as detected by ELISA. IgG binding to CL and beta 2GPI in the LIA was significantly lower in aPL+ carriers and Venereal Disease Research Laboratory test (VDRL) + samples than in patients with APS. HumoAb against domain 1 recognized beta 2GPI bound to the LIA-matrix and in anionic phospholipid (PL) complexes. Absorption with CL micelles abolished the reactivity of a PL-specific humoAb but did not affect the binding of anti-beta 2GPI humoAbs. Conclusions: The LIA and ELISA have good agreement in detecting aPL in APS, but the LIA differentiates patients with APS from infectious patients and asymptomatic carriers, likely through the exposure of domain 1.
Background
Antiphospholipid antibodies (aPL) can be detected in asymptomatic carriers and infectious patients. The aim was to investigate whether a novel line immunoassay (LIA) differentiates between antiphospholipid syndrome (APS) and asymptomatic aPL+ carriers or patients with infectious diseases (infectious diseases controls (IDC)).
Methods
Sixty-one patients with APS (56 primary, 22/56 with obstetric events only, and 5 secondary), 146 controls including 24 aPL+ asymptomatic carriers and 73 IDC were tested on a novel hydrophobic solid phase coated with cardiolipin (CL), phosphatic acid, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, beta2-glycoprotein I (β2GPI), prothrombin, and annexin V. Samples were also tested by anti-CL and anti-β2GPI ELISAs and for lupus anticoagulant activity. Human monoclonal antibodies (humoAbs) against human β2GPI or PL alone were tested on the same LIA substrates in the absence or presence of human serum, purified human β2GPI or after CL-micelle absorption.
Results
Comparison of LIA with the aPL-classification assays revealed good agreement for IgG/IgM aß2GPI and aCL. Anti-CL and anti-ß2GPI IgG/IgM reactivity assessed by LIA was significantly higher in patients with APS versus healthy controls and IDCs, as detected by ELISA. IgG binding to CL and ß2GPI in the LIA was significantly lower in aPL+ carriers and Venereal Disease Research Laboratory test (VDRL) + samples than in patients with APS. HumoAb against domain 1 recognized β2GPI bound to the LIA-matrix and in anionic phospholipid (PL) complexes. Absorption with CL micelles abolished the reactivity of a PL-specific humoAb but did not affect the binding of anti-β2GPI humoAbs.
Conclusions
The LIA and ELISA have good agreement in detecting aPL in APS, but the LIA differentiates patients with APS from infectious patients and asymptomatic carriers, likely through the exposure of domain 1.
• Möglichkeiten und Grenzen der Zivilgesellschaft beim Schutz der Grundrechte der Bürger • Die Enquete-Kommission Ethik und Recht der modernen Medizin des Deutschen Bundestags • Wie ernst sollen die Menschenrechte genommen werden? – Interview mit Ronald Dworkin • EU-Netzwerk unabhängiger Grundrechtsexperten • IGH: Demokratische Republik Kongo ./. Uganda
Neue Entwicklungen
(2006)
Vorwort: Im vorliegenden Heft der Studien zu Grund- und Menschenrechten wird der Vortrag dokumentiert, den Prof. Dr. Georg Lohmann von der Ottovon- Guericke-Universität Magdeburg am 12. Mai 2004 im Rahmen der neu eingerichteten Reihe „Philosophie der Grund- und Menschenrechte“ an der Universität Potsdam gehalten hat. Die Veranstaltung bot Gelegenheit, die Frage zu erörtern, ob die unterschiedlichen Menschenrechte tatsächlich gleichgestellt sind oder doch eine Hierarchisierung von Menschenrechten stattfindet. Diese Diskussion soll in diesem Heft durch den Abdruck von drei Kommentaren zum Vortrag nachvollzogen werden. Inhalt: Die Menschenrechte: unteilbar und gleichgewichtig? (Georg Lohmann) Kommentare Sinn der Menschenrechte (Stefan Gosepath) Die Menschenrechte: teilbar und ungleichgewichtig! (Arnd Pollmann) Zur Unteilbarkeit der Menschenrechte – Anmerkungen aus juristischer, insbesondere völkerrechtlicher Sicht (Claudia Mahler/Norman Weiß)